Stem cell shortcut: no extra drug, same recovery time?
NCT ID NCT03317899
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study looked at whether people with multiple myeloma or non-Hodgkin lymphoma who get a stem cell transplant can safely skip a drug called tbo-filgrastim (G-CSF) after the transplant. The drug is normally used to help white blood cells recover faster. The goal was to see if skipping it still allows patients to leave the hospital in about the same number of days. The trial involved 77 participants and compared recovery times between those who got the drug and those who did not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.